Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Disease area: Airway diseases, Interstitial lung diseases

Abstract

Introduction: A lysyl oxidase like 2 (LOXL2) directed monoclonal antibody (simtuzumab) is being clinically evaluated for the treatment of various fibrotic diseases including idiopathic pulmonary fibrosis (IPF).Objective: To characterize small molecule LOXL2 inhibitors biochemically and in functional assays to assess anti-fibrotic activity.Methods: High throughput screening was used to identify small molecule LOXL2 inhibitors. Screening hits were profiled for biochemical inhibition of LOXL2 and closely related amine oxidases (AOs). Binding to LOXL2 was confirmed by surface plasmon resonance (SPR) methods. Mechanistic experiments were used to judge substrate activity, reversibility, and allosteric and/or non-competitive LOXL2 inhibition. A novel collagen cross-linking assay was developed to evaluate the inhibitors.Results: Both reversible and irreversible LOXL2 inhibitors from various chemotypes were identified with biochemical IC50s of <500nM. LOXL2 binding was independently confirmed by SPR. Selectivity of >100-fold over monoamine oxidase A and B was achieved. Lead molecules demonstrated low micromolar inhibition of collagen cross-linking.Conclusions: We have identified novel LOXL2 selective small molecule inhibitors, which demonstrate activity in functional assays relevant to fibrosis.

Rating:

Share or cite this content

Citations should be made in the following way:
R. Rajagopalan, S. Misialek, J. X. Huang, L. Hooi, H. Ramesha, J. Nicholas, J. Ramphal, K. Emayan, L. Pan, S. Yap, L. Huang, S. Seiwert, B. Buckman (Brisbane, United States Of America). Biochemical and functional characterization of lysyl oxidase like 2 (LOXL2) inhibitors. Eur Respir J 2014; 44: Suppl. 58, 1518

Member's Comments

No comment yet.

Related content which might interest you: Pre-clinical evaluation of a novel and selective PI3K δ/gamma inhibitor in pulmonary fibrosis Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Inhibitor effect of Janus kinase II in bleomycin-induced pulmonary fibrosis model Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Erythropoietin (EPO) inhibits the immunohistochemical expression of lysyl oxidase (LOX) in bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Lipoxin (LXA4) as a novel therapy for idiopathic pulmonary fibrosis Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Proteasome function in lung fibrosis Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Elevated protein arginine methyltransferase 1 expression contributes to the pathogenesis of pulmonary fibrosis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Type II transmembrane serine protease matriptase is a mediator of pulmonary fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The effect of dasatinib, a novel tyrosine kinase inhibitor, on the regression of pulmonary fibrosis in mice Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 AAV-Tgfb1 vs. bleomycin: Analysis of gene expression profiles in two models of pulmonary fibrosis Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer Year: 2014 Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Molecular mechanisms of pirfenidone activity in human lung fibroblasts Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Development of secretory leukocyte protease inhibitor (SLPI) variants resistant to degradation by neutrophil elastase Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases Year: 2014 Altered protein homeostasis in pulmonary fibrosis indicates a role for proteasomal activator 200 Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Mitochondrial tRNA gene mutations in patients with idiopathic pulmonary fibrosis (IPF) and sarcoidosis Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Loss of CARM1 prolongs bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014 Metformin inhibits TGF-b-induced myofibroblast differentiation through AMPK activation Source: International Congress 2014 – Cell biology 2014 Year: 2014